UMLS:C0019204 - FACTA Search

Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Target Concepts:

Query: UMLS:C0019204 (hepatocellular carcinoma)
71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Apurinic/apyrimidinic (AP) sites are mutagenic and block DNA synthesis in vitro. Repair of AP sites is initiated by AP endonucleases that cleave just 5' to the damage. We linked a 4.1-kilobase pair HindIII DNA fragment from the region upstream of the human AP endonuclease gene (APE) to the chloramphenicol acetyltransferase (CAT) gene. Deletions generated constructs containing 1.9 kilobase pairs to 50 base pairs (bp) of the APE upstream region. Transient transfection studies in HeLa cells established that the basal APE promoter is contained within a 500-bp fragment. The major transcriptional start site in HeLa, hepatoma (HepG2), and myeloid leukemic (K562) cells was mapped to a cluster of sites approximately 130 bp downstream of a putative "CCAAT box," approximately 130 bp 5' of the first splice junction in APE. Deletion of 5' sequences to within 10 bp of the CCAAT box reduced the CAT activity by only about half, and removal of the CCAAT box region left a residual promotor activity approximately 9%. Deletion to 31 bp upstream of the transcriptional start site abolished APE promoter activity. DNA sequence analysis revealed potential transcription factor recognition sites in the APE promoter. Gel mobility-shift assays showed that both human upstream factor and Sp1 can bind their respective sites in the APE promoter. However, DNase I footprinting using HeLa nuclear extract showed that the binding of Sp1 and upstream factor is blocked by the binding of other proteins to the nearby CCAAT box region.
...
PMID:Characterization of the promoter region of the human apurinic endonuclease gene (APE). 753 97

The mouse alpha-fetoprotein (AFP) gene is transcribed at high levels in the visceral endoderm of the yolk sac and fetal liver and at much lower rates in the endoderm of the fetal gut. Expression of the gene in vivo requires the presence of at least one of three enhancers which lie in its 5' flanking region. In this report, we establish that the most distal AFP enhancer directed consistent expression of a linked AFP minigene in all three endodermal tissues in transgenic mice. The enhancer is composed of three domains, each of which is essential for full enhancer function by transient transfection assays. DNase I footprinting identified three regions of the enhancer which are protected by human hepatoma nuclear extracts, one of which corresponded to a consensus site for HNF-3 binding. Site-directed mutations in this site caused a 10-fold reduction in enhancer function by transient transfection. In transgenic mice, however, the mutation resulted in sporadic expression of the transgene, dependent on the site of integration. A similar acquisition of position-dependent sporadic expression of the transgene was observed with a mutation in a second protein binding site, despite the fact that this mutation had very little effect on enhancer function as assessed by transient transfection. These studies underscore the value of examining the functions of specific protein binding sites in vivo.
...
PMID:Molecular analysis of the distal enhancer of the mouse alpha-fetoprotein gene. 754 Jul 20

The rat tyrosine aminotransferase gene is a model system to study transcriptional regulation by glucocorticoid hormones. We analyzed transcription factor binding to the tyrosine aminotransferase gene glucocorticoid-responsive unit (GRU) at kb -2.5, using in vivo footprinting studies with both dimethyl sulfate and DNase I. At this GRU, glucocorticoid activation triggers a disruption of the nucleosomal structure. We show here that various regulatory pathways affect transcription factor binding to this GRU. The binding differs in two closely related glucocorticoid-responsive hepatoma cell lines. In line H4II, glucocorticoid induction promotes the recruitment of hepatocyte nuclear factor 3 (HNF3), presumably through the nucleosomal disruption. However, the footprint of the glucocorticoid receptor (GR) is not visible, even though a regular but transient interaction of the GR is necessary to maintain HNF3 binding. In contrast, in line FTO2B, HNF3 binds to the GRU in the absence of glucocorticoids and nucleosomal disruption, showing that a "closed" chromatin conformation does not repress the binding of certain transcription factors in a uniform manner. In FTO2B cells, the footprint of the GR is detectable, but this requires the activation of protein kinase A. In addition, protein kinase A stimulation also improves the recruitment of HNF3 independently of glucocorticoids and enhances the glucocorticoid response mediated by this GRU in an HNF3-dependent manner. In conclusion, the differences in the behavior of this regulatory sequence in the two cell lines show that various regulatory pathways are integrated at this GRU through modulation of interrelated events: transcription factor binding to DNA and nucleosomal disruption.
...
PMID:Glucocorticoids and protein kinase A coordinately modulate transcription factor recruitment at a glucocorticoid-responsive unit. 756 84

Glucokinase (GK) gene transcription occurs in the liver and the beta cell of the endocrine pancreas where it is subject to different modes of regulation. This is accomplished largely through the use of two linked, cell-specific promoters separated by at least 12 kbp. We have used DNase I hypersensitivity to explore the chromatin structure surrounding the two promoters in cells that express either the liver or beta cell form of the GK gene, as well as cells that do not express GK. In RIN38 cells, a beta-cell-derived cell line, hypersensitive sites are detected over both the proximal and distal promoters. In liver, hypersensitive sites are present in the proximal promoter but not the distal promoter. Interestingly, in H4IIEC3 cells, a hepatoma cell line that has lost the ability to express GK, hypersensitive sites are also found in the proximal promoter but not the distal promoter.
...
PMID:Cell specific differences in DNase I hypersensitivity between the two promoters of the rat glucokinase gene. 757 1

The expression of multidrug resistance/P-glycoprotein genes mdr1b(mdr1) and mdr1a(mdr3) is elevated during hepatocarcinogenesis. To investigate the regulation of mdr1b gene expression, we used transient transfection expression assays of reporter constructs containing various 5'-mdr1b flanking sequences in hepatoma and non-hepatoma cells. We found that nucleotides -233 to -116 preferentially enhanced the expression of reporter gene in mouse hepatoma cell lines in an orientation- and promoter context-independent manner. DNase I footprinting using nuclear extracts prepared from hepatoma and non-hepatoma cells identified four protein binding sites at nucleotides -205 to -186 (site A), -181 to -164 (site B), -153 to -135 (site C), and -128 to -120 (site D). Further analyses revealed that, while site B alone played a major part for the enhancer function, sites A and B combined conferred full enhancer activity. Site-directed mutagenesis results also supported these results. Gel retardation experiments using oligonucleotide competitors revealed that the site B contains a dominant binding protein. This is the first report demonstrating a cell type-specific enhancer in the mdr locus. The role of this enhancer in the activation of mdr1b gene during hepatocarcinogenesis is discussed.
...
PMID:Identification and characterization of a hepatoma cell-specific enhancer in the mouse multidrug resistance mdr1b promoter. 759 15

Fibronectin (FN) is a widely distributed extracellular matrix protein that is essential for cell adhesion in a variety of biological processes such as wound healing, tissue development and remodeling and oncogenic transformation. Appropriate FN levels are obtained by induction or repression of the FN gene in response to specific factors or circumstances in vivo. In order to identify regulatory regions involved in tissue-specific expression of FN, we have examined the transcriptional activity of overlapping fragments, within 4 kb upstream of the rat FN gene, following transfection into different cell types. Two regions conferred increases in transcription. The region between -1.08 and -2.6 displayed tissue-specificity and was active in fibroblasts but not hepatoma cells. The second region, between -3.2 and -3.9, was active in both cell types. Further characterization of the -1.08 to -2.6 segment demonstrated that it acts as an enhancer. Exonuclease III deletions of the 3' and 5' ends of the enhancer localized essential sequences between -1.5 and -1.7 and indicate that this fragment acts in concert with other sites between -1.08 and -2.6 to provide maximum enhancer activity. Gel mobility shift assays demonstrated fibroblast-specific binding of nuclear protein(s) to a 65 bp fragment within the essential region and DNase I footprinting localized this binding to a 27 bp sequence. Deletion of the sequence abolished the activity of the 1.5 kb enhancer. These studies show that a novel DNA sequence at -1688 is involved in regulating transcription of the FN gene in fibroblasts.
...
PMID:Identification of an enhancer involved in tissue-specific regulation of the rat fibronectin gene. 766 11

In hepatocytes, insulin-like growth factor-binding protein-1 (IGFBP-1) levels are increased by glucocorticoids and by agents that raise intracellular cAMP levels such as glucagon, theophylline, forskolin, and cAMP analogues. In contrast, insulin lowers IGFBP-1 levels, an effect dominant over the glucocorticoid and cAMP effects. Previous studies showed that dibutyryl cAMP (Bt2cAMP) and theophylline increase IGFBP-1 promoter activity in HEP G2 human hepatoma cells and that insulin abolishes this increase. In studies reported here, HEP G2 cells were used to further evaluate the role of cAMP in stimulating IGFBP-1 expression. Initial studies found that either 0.5 or 5.0 mM Bt2cAMP alone, or the combination of 0.5 mM Bt2cAMP and 2 mM theophylline, increased IGFBP-1 protein levels, mRNA levels, and promoter activity, but that the addition of theophylline to Bt2cAMP was required to give a approximately 5-fold increase in promoter activity. Deletion mutations of the IGFBP-1 promoter were used to show that much of the effect of Bt2cAMP and theophylline was conferred by the region between 269 and 246 base pairs (bp) 5' of the IGFBP-1 mRNA cap site. DNase I protection assays showed that HEP G2 nuclear extract footprinted the region from 273 to 249 bp 5' of the cap site; this region, designated P2, has a central CGTCA motif common to cAMP-responsive elements (CREs). Mutating the CGTCA motif in the 1205-bp IGFBP-1 promoter construct to TAGCA led to a 51% decrease in the ability of Bt2cAMP and theophylline to stimulate IGFBP-1 promoter activity above control levels. In addition, cotransfection of the catalytic subunit of cAMP-dependent protein kinase A (PKA) with the native 1205-bp IGFBP-1 promoter construct stimulated IGFBP-1 promoter activity 3.9-fold, but the TAGCA mutation decreased by 73% the ability of PKA to stimulate IGFBP-1 promoter activity above control levels. Mutating the CGTCA motif to TAGCA also blocked the ability of both crude HEP G2 nuclear extract and recombinant CRE-binding protein to bind to the P2 element. These data suggest that the P2 element is a CRE that confers at least part of the stimulatory effect of cAMP on the human IGFBP-1 promoter.
...
PMID:Identification of a promoter element which participates in cAMP-stimulated expression of human insulin-like growth factor-binding protein-1. 768 58

The P450/6 beta A (CYP3A2) gene encoding a testosterone 6 beta-hydroxylase is expressed predominantly in liver and induced by the treatment of rats with various compounds. To understand the mechanism of the basal transcriptional activation of the CYP3A2 gene, the cis-acting elements in the proximal promoter region (-165 to -73) of the CYP3A2 gene were identified in this study. Nuclear extract from rat livers interacted with three sites, 6 beta A-A (-106 to -87), 6 beta A-B (-140 to -119) and 6 beta A-C (-163 to -145). These sites were detectable by DNase I footprinting and gel mobility shift assays and found to share nucleotide sequence similarity with each other (T(A/C)(A/C)N(A/G)AAG(G/T)(C/T)CA). Direct repeats of AGTTCA (-134 to -120) and AG(G/C)TCA (-162 to -148) are also detected in 6 beta A-B and 6 beta A-C sites, respectively. To elucidate the relationship of these sites with basal transcriptional activation of the CYP3A2 gene, varying lengths of the proximal promoter region (-164 to +41) fused to a CAT reporter gene were transfected in human hepatoma (HepG2) and mouse adrenal tumor (Y-1) cells. The relative level of CAT activity in HepG2 cells was slightly increased by the deletion of the 5'-portion from -164 to -111 bp, but was reduced to 14% of the control (the construct including from -110 to +41) by the deletion from -110 to -81 including the 6 beta A-A site. On the other hand, these deletions have no clear effect on the level of the activity in Y-1 cells. Substitution mutations at two nucleotides in the 6 beta A-A site resulted in the reduction of CAT activity in HepG2 cells to 12% of the activity in the wild-type construct. The interaction of an oligonucleotide corresponding to the 6 beta A-A site (-106 to -87) with liver nuclear factors was completely inhibited by the addition of a typical oligonucleotide for hepatocyte nuclear factor-4 (HNF-4) binding site (F. M. Sladek, W. Zhong, E. Lai, and J. E. Darnell, Jr., 1990, Genes Dev. 4, 2353-2365) but not of oligonucleotides corresponding to 6 beta A-B or 6 beta A-C sites. These results suggest an essential role of the binding of HNF-4 and/or HNF-4-related nuclear factors to the 6 beta A-A site on the basal transcriptional activation of the CYP3A2 gene in liver cells.
...
PMID:Transcriptional elements directing a liver-specific expression of P450/6 beta A (CYP3A2) gene-encoding testosterone 6 beta-hydroxylase. 772 76

The influence of hepatocyte nuclear factor 3 (HNF3) on the level of transcriptional activity from the four hepatitis B virus promoters was investigated by transient-transfection analysis in the dedifferentiated hepatoma cell line, HepG2.1. It was found that the large surface antigen promoter and, to a much lesser extent, the nucleocapsid promoter were transactivated in the presence of HNF3. DNase I footprinting analysis demonstrated that purified recombinant HNF3 alpha protects one region of the large surface antigen promoter. Gel retardation analysis showed that a double-stranded oligonucleotide containing this HNF3-binding site formed a specific complex with DNA-binding proteins in the differentiated hepatoma cell lines, Huh7 and HepG2. The complex formed with Huh7 cell extract comigrated with exogenously expressed HNF3 beta in HeLa S3 extracts and was specifically inhibited from forming by the addition of HNF3 beta antiserum. The promoter element which appears to mediate the HNF3 transactivation was functionally mapped by mutational analysis to a region between nucleotides -65 and -54 relative to the transcriptional start site. This regulatory sequence is within the region protected from DNase I digestion by HNF3 alpha and contains 10 of 12 nucleotides homologous to the HNF3-binding-site consensus sequence. A synthetic promoter construct containing this HNF3-binding site was able to mediate transactivation by HNF3 beta. These and previous results suggest that the hepatitis B virus large surface antigen promoter is regulated by at least two liver-enriched transcription factors, HNF1 and HNF3, which together may contribute to the differentiated liver cell type specificity of this promoter.
...
PMID:Regulation of transcription from the hepatitis B virus large surface antigen promoter by hepatocyte nuclear factor 3. 774 73

In previous studies, we identified a 21 bp palindrome (-794 to -774) located within the negative regulatory element of the human CYP1A1 gene consisting of an 8 bp inverted repeat and 5 bp spacer. This element specifically binds protein(s) present in HepG2 nuclear extract preparations and is capable of down-regulating heterologous promoters and enhancers in transient expression assays. Conserved guanine/cytosine-rich regions which flank the palindrome also were implicated in this activity. In the present study, we examined similar regions from the rat (-881 to -746) and mouse (-822 to -683) CYP1A1 genes for their ability to bind nuclear protein and down-regulate heterologous promoters and enhancers. These rodent DNA fragments contain the conserved guanine/cytosine-rich sequences, as well as half-sites similar to those found in the human CYP1A1 palindrome. However, each half-site is separated by approximately 40 bp. DNase I footprint analyses revealed the presence of rat and mouse nuclear proteins which gave a similar protection pattern as that observed with nuclear proteins from the human cell line, HepG2. Electrophoretic mobility shift assays with the human negative regulatory element demonstrated the formation of specific DNA-protein complexes with rat and mouse nuclear protein(s). Interestingly, two specific DNA-protein complexes were observed with rodent extracts as compared to the single specific complex seen with human extract. Specific binding was not observed with either the orthologous rat or mouse fragments using human or rodent extracts. In transient expression assays, the rat and mouse fragments were unable to down-regulate enhancer/promoter activity. This absence of negative regulatory activity occurred whether transfections were performed in human, rat or mouse hepatoma cell lines. The human negative regulatory element, which was previously shown to down-regulate heterologous enhancers/promoters approximately 70% in human cells, did not exhibit this activity in rodent cell lines. UV cross-linking and southwestern blot analyses indicated a high degree of similarity between human and rodent NRE binding proteins, although some differences also were apparent. The possible implications of these findings with regards to species differences in the regulation of CYP1A1 expression are discussed.
...
PMID:In vitro binding and functional studies comparing the human CYP1A1 negative regulatory element with the orthologous sequences from rodent genes. 785 71

<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>